Abbott Cephea Mitral Valve Disease Registry

Inclusion Criteria:

1. Symptomatic mitral valve disease resulting in mitral regurgitation and/or severemitral valve stenosis.

2. New York Heart Association (NYHA) Functional Class II, III, or ambulatory IV.

3. In the judgement of the Site Heart Team, transcatheter therapy is deemed to be moreappropriate than conventional mitral valve surgery, TMVR is more likely to providean optimal result than TEER, and the subject has been adequately treated perapplicable standards, including for coronary artery disease, left ventriculardysfunction, and heart failure.

4. Age 18 years or older at time of consent.

5. The subject agrees to the study requirements, permits all follow-up data entry, andhas provided written informed consent.

Exclusion Criteria:

1. Prior surgical or interventional treatment that interferes with the Cephea valvedelivery or function.

2. Subject is undergoing dialysis or experiencing chronic renal failure

3. Subject has chronic lung disease requiring continuous home oxygen therapy or chronicoutpatient oral steroid use

4. Subjects with comorbidities that are likely to result in a life expectancy of lessthan 12 months.

5. Pregnant or nursing subjects and those who plan pregnancy during the follow-upperiod.